Spurred by evidence that androgens remain a key factor in the progression of hormone-refractory prostate cancer, novel approaches to hormonal manipulation have begun the transit from laboratory to clinical evaluation, and some of the preliminary results are encouraging.
Developments in stem cell therapy, new minimally invasive sling procedures, and research on botulinum toxin (Botox) therapy for overactive bladder soon will give urologists far more effective treatment for incontinence than they can offer their patients today.
A baseline bone density test to screen for osteoporosis, simple lifestyle changes to prevent osteoporosis from developing, and aggressive treatment if it develops are strongly recommended for men on androgen deprivation therapy (ADT) for advanced prostate cancer.
Many standard laboratory techniques could soon become clinical practice for the diagnosis and treatment of male infertility.
It's been a long time since urologists have been able to offer interstitial cystitis patients anything new and effective, but that day may be here for patients with the most severe disease.
Reconstructive urology continues to be advanced by the development of innovative techniques and technologies, while new long-term data reinforce the promise of older approaches that have withstood the test of time.
Basic research should soon bring urologists entirely new ways to thwart or treat urinary tract infection, which could be welcome eleventh-hour saves from the problem of antibiotic-resistant bacteria.
Two innovative technologies for surgical training are approaching urologic practice, but how long it will take for them to arrive depends on the hurdles they must leap.
Sexual dysfunction comprises more than erectile dysfunction, and other conditions that fall into the category often receive a disproportionate amount of public attention.
A number of minimally invasive treatments are allowing millions of men to avoid a lifetime of medications or major surgical intervention for treatment of BPH.
The 2007 AUA Annual Meeting begins May 19th at the Anaheim Convention Center in Anaheim, California. In this podcast, Richard Kerr, the editor-in-chief of Urology Times provides us with an overview of the meeting and Elaine Cali, VP of Communications for the Anahiem/Orange County Visitors and Convention Bureau shares a few ideas for making your visit to Southern California fun for the whole family.
Alternative therapies still hold great potential in treating BPH, prostatitis, and prostate cancer.
New products and services available to urologists.
images
images
David A. Bloom, MD, has been appointed chairman of the department of urology at the University of Michigan Medical School in Ann Arbor. Dr. Bloom, a pediatric urologic surgeon who is the Jack Lapides Professor of Urology, replaces James E. Montie, MD, who relinquished the chairmanship to continue his research on the quality of care for patients with urologic cancer.
Cosmos Trading, Inc., is conducting a voluntary nationwide recall of its dietary supplement product sold under the name Rhino Max (Rhino V Max) after lab analysis found that the product contains aminotadalafil, an analogue of tadalafil, making Rhino Max (Rhino V Max) an unapproved drug.
The American Association for Cancer Research (AACR) has announced the formation of the AACR-FDA-NCI Cancer Biomarkers Collaborative to facilitate the use of validated biomarkers in clinical trials and, ultimately, their use in evidence-based oncology and cancer medicine. The collaborative includes researchers from academia, government, and industry, as well as patient advocacy groups.
A new imaging technique, known as a functional diffusion map, can measure the effectiveness of treatment for prostate cancer metastatic to bone. The technique involves measuring diffusion of water within tumors.
The androgen receptor appears to play a key role in the development of bladder cancer, revealing why the disease is more prevalent in men than in women, according to a study published in the Journal of the National Cancer Institute (2007; 99:558-68). This finding could open the door to new types of treatment.
Radical prostatectomy, external beam radiation therapy, and brachytherapy affect a man's quality of life in different ways, according to a long-term study conducted by UCLA researchers. While the three treatment options rank about equally in survival outcomes in most men, specific effects on quality of life become paramount in making treatment decisions, said lead author Mark Litwin, MD.
Urologists and other physicians are facing another battle over Medicare fees, with a 9.9% cut looming for 2008 and further reductions that will be imposed on physicians who provide in-office imaging services as a result of the Deficit Reduction Act of 2005.
A predictive model that incorporates the androgen receptor concentration of prostate cancer cells can identify patients who have an increased risk of clinical failure 5 years after radical prostatectomy.
Recent research suggests that the common fusion of two genes may point to a molecular basis for prostate cancer.
Epidemiologic studies show that prostate cancer does not occur at the same rate all over the world.
Researchers at Johns Hopkins have made significant progress on the development of a new serum biomarker known as Early Prostate Cancer Antigen-2.
Products and services from manufacturers who are exhibiting at the American Urological Association meeting in Anaheim.
Those in town for AUA 2007 will be delighted to learn that Anaheim, heavily vested in tourism, offers a vast collection of culinary options to satisfy even the most discriminating appetite.
Once known as the strawberry-growing capital of the United States, the area is cultivating a new field as a vacation destination, with something for every age and every interest, from scuba and baseball, to shopping and wine tours, to amusement parks, theater, and concerts, all within Anaheim proper or a short drive from the city.
